Please use this identifier to cite or link to this item:
DC FieldValueLanguage
dc.contributorChi Yangen_US
dc.contributor.authorKeng-Ying Liaoen_US
dc.identifier.citation1. Desilles JP, Syvannarath V, Ollivier V, et al. Exacerbation of Thromboinflammation by Hyperglycemia Precipitates Cerebral Infarct Growth and Hemorrhagic Transformation. Stroke 2017;48:1932-1940. 2. Dietrich WD, Alonso O, Busto R. Moderate hyperglycemia worsens acute blood-brain barrier injury after forebrain ischemia in rats. Stroke 1993;24:111-116. 3. Widmer H, Abiko H, Faden AI, et al. Effects of hyperglycemia on the time course of changes in energy metabolism and pH during global cerebral ischemia and reperfusion in rats: correlation of 1H and 31P NMR spectroscopy with fatty acid and excitatory amino acid levels. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 1992;12:456-468. 4. Harada S, Fujita-Hamabe W, Tokuyama S. Ischemic Stroke and Glucose Intolerance: a Review of the Evidence and Exploration of Novel Therapeutic Targets. Journal of Pharmacological Sciences 2012;118:1-13. 5. Huang J, Liu B, Yang C, et al. Acute hyperglycemia worsens ischemic stroke-induced brain damage via high mobility group box-1 in rats. Brain Res 2013;1535:148-155. 6. Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 2018;49:e46-e110. 7. Weir CJ, Murray GD, Dyker AG, et al. Is hyperglycaemia an independent predictor of poor outcome after acute stroke? Results of a long-term follow up study. BMJ (Clinical research ed) 1997;314:1303-1306. 8. Kuroki T, Tanaka R, Shimada Y, et al. Exendin-4 Inhibits Matrix Metalloproteinase-9 Activation and Reduces Infarct Growth After Focal Cerebral Ischemia in Hyperglycemic Mice. Stroke 2016;47:1328-1335. 9. Kagansky N, Levy S, Knobler H. The role of hyperglycemia in acute stroke. Archives of neurology 2001;58:1209-1212. 10. Pulsinelli WA, Waldman S, Rawlinson D, et al. Moderate hyperglycemia augments ischemic brain damage: a neuropathologic study in the rat. Neurology 1982;32:1239-1246. 11. Lin B, Ginsberg MD, Busto R. Hyperglycemic exacerbation of neuronal damage following forebrain ischemia: microglial, astrocytic and endothelial alterations. Acta neuropathologica 1998;96:610-620. 12. Hamilton MG, Tranmer BI, Auer RN. Insulin reduction of cerebral infarction due to transient focal ischemia. Journal of neurosurgery 1995;82:262-268. 13. Scott JF, Robinson GM, French JM, et al. Glucose potassium insulin infusions in the treatment of acute stroke patients with mild to moderate hyperglycemia: the Glucose Insulin in Stroke Trial (GIST). Stroke 1999;30:793-799. 14. Bruno A, Kent TA, Coull BM, et al. Treatment of hyperglycemia in ischemic stroke (THIS): a randomized pilot trial. Stroke 2008;39:384-389. 15. Ntaios G, Abatzi C, Alexandrou M, et al. Persistent hyperglycemia at 24-48 h in acute hyperglycemic stroke patients is not associated with a worse functional outcome. Cerebrovascular diseases (Basel, Switzerland) 2011;32:561-566. 16. Reshi R, Streib C, Ezzeddine M, et al. Hyperglycemia in acute ischemic stroke: Is it time to re-evaluate our understanding? Med Hypotheses 2017;107:78-80. 17. Capes SE, Hunt D, Malmberg K, et al. Stress Hyperglycemia and Prognosis of Stroke in Nondiabetic and Diabetic Patients: A Systematic Overview. Stroke 2001;32:2426-2432. 18. Harada S, Nozaki Y, Matsuura W, et al. Cerebral ischemia-induced elevation of hepatic inflammatory factors accompanied by glucose intolerance suppresses hypothalamic orexin-A-mediated vagus nerve activation. Brain Res 2017;1661:100-110. 19. Yao M, Ni J, Zhou L, et al. Elevated Fasting Blood Glucose Is Predictive of Poor Outcome in Non-Diabetic Stroke Patients: A Sub-Group Analysis of SMART. PLoS One 2016;11:e0160674. 20. Urabe T, Watada H, Okuma Y, et al. Prevalence of abnormal glucose metabolism and insulin resistance among subtypes of ischemic stroke in Japanese patients. Stroke 2009;40:1289-1295. 21. Bienek R, Marek B, Kajdaniuk D, et al. Adiponectin, leptin, resistin and insulin blood concentrations in patients with ischaemic cerebral stroke. Endokrynologia Polska 2012;63:338-345. 22. Jing J, Pan Y, Zhao X, et al. Insulin Resistance and Prognosis of Nondiabetic Patients With Ischemic Stroke: The ACROSS-China Study (Abnormal Glucose Regulation in Patients With Acute Stroke Across China). Stroke 2017;48:887-893. 23. Wang YY, Chen CJ, Lin SY, et al. Hyperglycemia is associated with enhanced gluconeogenesis in a rat model of permanent cerebral ischemia. Mol Cell Endocrinol 2013;367:50-56. 24. O'Shaughnessy CT, Rothwell NJ, Shrewsbury-Gee J. Sympathetically mediated hypermetabolic response to cerebral ischemia in the rat. Canadian journal of physiology and pharmacology 1990;68:1334-1337. 25. Wang YY, Lin SY, Chuang YH, et al. Adipose proinflammatory cytokine expression through sympathetic system is associated with hyperglycemia and insulin resistance in a rat ischemic stroke model. Am J Physiol Endocrinol Metab 2011;300:E155-163. 26. Wang YY, Lin SY, Chuang YH, et al. Activation of hepatic inflammatory pathways by catecholamines is associated with hepatic insulin resistance in male ischemic stroke rats. Endocrinology 2014;155:1235-1246. 27. van Kooten F, Hoogerbrugge N, Naarding P, et al. Hyperglycemia in the acute phase of stroke is not caused by stress. Stroke 1993;24:1129-1132. 28. Smith KE, Hachinski VC, Gibson CJ, et al. Changes in plasma catecholamine levels after insula damage in experimental stroke. Brain Res 1986;375:182-185. 29. Park S, Kim DS, Kang S. Exercise training attenuates cerebral ischemic hyperglycemia by improving hepatic insulin signaling and beta-cell survival. Life Sci 2013;93:153-160. 30. Seyfizadeh N, Seyfizadeh N, Gharibi T, et al. Interleukin-13 as an important cytokine: A review on its roles in some human diseases. Acta Microbiol Immunol Hung 2015;62:341-378. 31. Edwards JP, Zhang X, Frauwirth KA, et al. Biochemical and functional characterization of three activated macrophage populations. J Leukoc Biol 2006;80:1298-1307. 32. McLaughlin T, Ackerman SE, Shen L, et al. Role of innate and adaptive immunity in obesity-associated metabolic disease. J Clin Invest 2017;127:5-13. 33. Odegaard JI, Ricardo-Gonzalez RR, Goforth MH, et al. Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature 2007;447:1116-1120. 34. Qiu Y, Nguyen KD, Odegaard JI, et al. Eosinophils and type 2 cytokine signaling in macrophages orchestrate development of functional beige fat. Cell 2014;157:1292-1308. 35. Russell MA, Morgan NG. The impact of anti-inflammatory cytokines on the pancreatic beta-cell. Islets 2014;6:e950547. 36. Zaccone P, Phillips J, Conget I, et al. Interleukin-13 prevents autoimmune diabetes in NOD mice. Diabetes 1999;48:1522-1528. 37. Darkhal P, Gao M, Ma Y, et al. Blocking high-fat diet-induced obesity, insulin resistance and fatty liver by overexpression of Il-13 gene in mice. Int J Obes (Lond) 2015;39:1292-1299. 38. Stanya KJ, Jacobi D, Liu S, et al. Direct control of hepatic glucose production by interleukin-13 in mice. J Clin Invest 2013;123:261-271. 39. Kawahara K, Suenobu M, Yoshida A, et al. Intracerebral microinjection of interleukin-4/interleukin-13 reduces beta-amyloid accumulation in the ipsilateral side and improves cognitive deficits in young amyloid precursor protein 23 mice. Neuroscience 2012;207:243-260. 40. Ma XM, Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nature reviews Molecular cell biology 2009;10:307-318. 41. Fluri F, Schuhmann MK, Kleinschnitz C. Animal models of ischemic stroke and their application in clinical research. Drug Des Devel Ther 2015;9:3445-3454. 42. Isayama K, Pitts LH, Nishimura MC. Evaluation of 2,3,5-triphenyltetrazolium chloride staining to delineate rat brain infarcts. Stroke 1991;22:1394-1398. 43. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419. 44. Hatting M, Tavares CDJ, Sharabi K, et al. Insulin regulation of gluconeogenesis. Ann N Y Acad Sci 2018;1411:21-35. 45. O'Brien RM, Lucas PC, Forest CD, et al. Identification of a sequence in the PEPCK gene that mediates a negative effect of insulin on transcription. Science (New York, NY) 1990;249:533-537. 46. Oto J, Suzue A, Inui D, et al. Plasma proinflammatory and anti-inflammatory cytokine and catecholamine concentrations as predictors of neurological outcome in acute stroke patients. Journal of anesthesia 2008;22:207-212. 47. Kim JH, Bachmann RA, Chen J. Interleukin-6 and insulin resistance. Vitamins and hormones 2009;80:613-633. 48. Sosale B, Chandrashekara S, Aravind SR, et al. Influence of cytokine status on insulin resistance and circulating endothelial progenitor cells in type 2 diabetes mellitus. Cytokine 2017;99:179-185. 49. Xiong X, Barreto GE, Xu L, et al. Increased brain injury and worsened neurological outcome in interleukin-4 knockout mice after transient focal cerebral ischemia. Stroke 2011;42:2026-2032. 50. Famakin B, Mou Y, Spatz M, et al. Downstream Toll-like receptor signaling mediates adaptor-specific cytokine expression following focal cerebral ischemia. J Neuroinflammation 2012;9:174. 51. Kim HA, Whittle SC, Lee S, et al. Brain immune cell composition and functional outcome after cerebral ischemia: comparison of two mouse strains. Front Cell Neurosci 2014;8:365. 52. Nie Y, Erion DM, Yuan Z, et al. STAT3 inhibition of gluconeogenesis is downregulated by SirT1. Nat Cell Biol 2009;11:492-500. 53. Ramadoss P, Unger-Smith NE, Lam FS, et al. STAT3 targets the regulatory regions of gluconeogenic genes in vivo. Molecular endocrinology (Baltimore, Md) 2009;23:827-837. 54. Kim JH, Kim JE, Liu HY, et al. Regulation of interleukin-6-induced hepatic insulin resistance by mammalian target of rapamycin through the STAT3-SOCS3 pathway. J Biol Chem 2008;283:708-715. 55. McCormick SM, Heller NM. Commentary: IL-4 and IL-13 receptors and signaling. Cytokine 2015;75:38-50. 56. Wang AJ, Yang Z, Grinchuk V, et al. IL-25 or IL-17E Protects against High-Fat Diet-Induced Hepatic Steatosis in Mice Dependent upon IL-13 Activation of STAT6. J Immunol 2015;195:4771-4780. 57. Souza PP, Brechter AB, Reis RI, et al. IL-4 and IL-13 inhibit IL-1beta and TNF-alpha induced kinin B1 and B2 receptors through a STAT6-dependent mechanism. Br J Pharmacol 2013;169:400-412. 58. Ricardo-Gonzalez RR, Red Eagle A, Odegaard JI, et al. IL-4/STAT6 immune axis regulates peripheral nutrient metabolism and insulin sensitivity. Proceedings of the National Academy of Sciences of the United States of America 2010;107:22617-22622. 59. Theodorou GL, Marousi S, Ellul J, et al. T helper 1 (Th1)/Th2 cytokine expression shift of peripheral blood CD4+ and CD8+ T cells in patients at the post-acute phase of stroke. Clin Exp Immunol 2008;152:456-463. 60. Lindsberg PJ, Roine RO. Hyperglycemia in acute stroke. Stroke 2004;35:363-364. 61. Wannamethee SG, Perry IJ, Shaper AG. Nonfasting serum glucose and insulin concentrations and the risk of stroke. Stroke 1999;30:1780-1786. 62. Tziomalos K, Dimitriou P, Bouziana S, et al. Transient hyperglycemia at admission and acute ischemic stroke severity and short-term outcome. Hellenic Journal οf Atherosclerosis 2016;7. 63. Serra-Perez A, Verdaguer E, Planas AM, et al. Glucose promotes caspase-dependent delayed cell death after a transient episode of oxygen and glucose deprivation in SH-SY5Y cells. Journal of neurochemistry 2008;106:1237-1247. 64. Cronberg T, Rytter A, Asztely F, et al. Glucose but not lactate in combination with acidosis aggravates ischemic neuronal death in vitro. Stroke 2004;35:753-757. 65. Faraco G, Fossati S, Bianchi ME, et al. High mobility group box 1 protein is released by neural cells upon different stresses and worsens ischemic neurodegeneration in vitro and in vivo. Journal of neurochemistry 2007;103:590-603. 66. Vemula S, Roder KE, Yang T, et al. A functional role for sodium-dependent glucose transport across the blood-brain barrier during oxygen glucose deprivation. J Pharmacol Exp Ther 2009;328:487-495. 67. Magnusson I, Rothman DL, Katz LD, et al. Increased rate of gluconeogenesis in type II diabetes mellitus. A 13C nuclear magnetic resonance study. J Clin Invest 1992;90:1323-1327. 68. Cieślak M, Wojtczak A, Cieślak M. Role of pro-inflammatory cytokines of pancreatic islets and prospects of elaboration of new methods for the diabetes treatment. Acta Biochimica Polonica 2015;62:15-21. 69. Buras ED, Yang L, Saha P, et al. Proinsulin-producing, hyperglycemia-induced adipose tissue macrophages underlie insulin resistance in high fat-fed diabetic mice. FASEB J 2015;29:3537-3548. 70. Russell MA, Cooper AC, Dhayal S, et al. Differential effects of interleukin-13 and interleukin-6 on Jak/STAT signaling and cell viability in pancreatic beta-cells. Islets 2013;5:95-105. 71. Priceman SJ, Kujawski M, Shen S, et al. Regulation of adipose tissue T cell subsets by Stat3 is crucial for diet-induced obesity and insulin resistance. Proceedings of the National Academy of Sciences of the United States of America 2013;110:13079-13084. 72. Kidd P. Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. Alternative medicine review : a journal of clinical therapeutic 2003;8:223-246. 73. Madhumitha H, Mohan V, Deepa M, et al. Increased Th1 and suppressed Th2 serum cytokine levels in subjects with diabetic coronary artery disease. Cardiovascular diabetology 2014;13:1. 74. Ezquer F, Ezquer M, Contador D, et al. The antidiabetic effect of mesenchymal stem cells is unrelated to their transdifferentiation potential but to their capability to restore Th1/Th2 balance and to modify the pancreatic microenvironment. Stem Cells 2012;30:1664-1674.zh_TW
dc.description.abstractCerebral ischemia (stoke) is one of the leading causes of death and disability worldwide, whereas hyperglycemia is known as a risk factor for stroke prognosis. Post-ischemic hyperglycemia happens to about 8-63% acute ischemic stroke patients even without preexisting diabetes, which might cause poor prognosis, higher mortality, and impaired neurological recovery. However, with the unknown mechanism, there has not been a protocol for treating post-ischemic hyperglycemia. On the other hand, research found that acute stroke secretes counter-regulatory hormones, pro-inflammatory cytokines, and other regulatory factors, which enhances insulin resistance. Interleukin-13 (IL-13), as a member of the Th2 anti-inflammatory cytokine family, was reported to be involved in glucose hemostasis. Studies showed that IL-13 is capable of enhancing insulin sensitivity and suppressing hepatic gluconeogenesis, and that overexpressing IL-13 reverses abnormal glucose metabolism and insulin resistance in obese mice. Thus, we aim to discuss the mechanism of post-ischemic hyperglycemia and the role IL-13 may play in this phenomena through permanent middle artery occlusion rat model. Our results showed that post-ischemic hyperglycemia was accompanied by elevated insulin resistance index, elevated serum insulin concentration, elevated hepatic gluconeogenesis, and decreased insulin signaling. Meanwhile, systemic pro-inflammatory cytokine was also found significantly elevated and anti-inflammatory cytokine decreased. With IL-13 treatment, the above pathological state was reversed due to the JAK1/STAT6 signaling activation, which shifted the inflammatory state towards Th2 immunity. Our findings suggest that IL-13 treatment may be a new perspective for the prevention and control of post-ischemic hyperglycemia.en_US
dc.description.tableofcontents1. Introduction and paper review…………………………………………………1 2. Materials and Methods…………………………………………………………10 3. Results…………………………………………………………………………14 4. Discussion……………………………………………………………………25 5. References……………………………………………………………………32zh_TW
dc.subjectInsulin resistanceen_US
dc.subjectTh2 immunityen_US
dc.titleControl of post-ischemic hyperglycemia with Interleukin-13 by inhibiting metabolic pro-inflammatory state and insulin resistance in permanent cerebral ischemia rat modelen_US
dc.typethesis and dissertationen_US
item.fulltextwith fulltext-
item.openairetypethesis and dissertation-
Appears in Collections:獸醫學系所
Files in This Item:
File SizeFormat Existing users please Login
nchu-107-7105038202-1.pdf864.54 kBAdobe PDFThis file is only available in the university internal network    Request a copy
Show simple item record

Google ScholarTM


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.